• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
Addiction Treatment Forum

Addiction Treatment Forum

Addiction Treatment Forum reports on substance use news of interest to opioid treatment programs and patients in medication-assisted treatment.

  • Newsletter
  • Addiction Resources
  • Methadone
  • Buprenorphine
  • Patient Brochures
  • Events

A Significant Decline in Criminal Charges Seen With Methadone Treatment—not With Buprenorphine Treatment  

June 7, 2016 by Barbara Goodheart, ELS

crime

 A key goal in addiction treatment is to reduce the criminal activity associated with substance use disorders. Several studies have shown that a reduction does occur with methadone treatment, but less has been reported about buprenorphine treatment.

The authors of the current study compared criminal charges in patients two years before and two years after their enrollment in either methadone or office-based buprenorphine treatment. Therapy included individual and group counseling, cognitive-behavioral motivational intervention, and contingency contracting. The intensity and frequency of counseling were increased for patients with poor attendance records or drug-positive urine tests.

At study’s end, the methadone group showed a statistically significant decline in proportion of subjects with any charges, especially the proportion with drug charges. A significant drop also occurred in the average number of criminal cases, and in the number of drug cases. The buprenorphine group did not show significant changes in any of these measures. Substance Use & Misuse published the study online April 20.

Study Details 

Subjects

Enrollees in methadone (252) or buprenorphine (252) treatment, 2003-2007

Objectives

1.) To compare criminal charges before and after enrollment; 2.) to examine risk factors for criminal charges in the two years after enrollment

Methods

Reviewed demographic data from medical records; collected data on criminal charges from a state-maintained data base; used multivariable analysis to assess risk factors

Results

1.) Methadone patients (but not buprenorphine patients) showed a significant decline in the four preassigned measures; buprenorphine patients showed no significant changes in any measure; 2.) the strongest predictor of criminal charges two years after enrollment was prior charges

Conclusions

Buprenorphine treatment did not seem to have the same beneficial effect as methadone treatment on criminal charges two years after enrollment

Several factors could have contributed to the drop:

  • Methadone patients are under more intensive treatment and closer observation than buprenorphine patients
  • Methadone—a full agonist—may be more effective than buprenorphine at suppressing craving
  • Buprenorphine patients have a better opportunity to sell their medication
  • Some buprenorphine patients may have been charged with possession only because they were carrying their prescribed medication

Authors’ Comments

To conclude that making office-based buprenorphine treatment more like methadone programs could be a mistake, the authors point out; it might discourage primary care physicians and alienate some patients. They suggest instead “to continue offering a spectrum of treatment options and to focus instead on matching patients to the optimal treatment, which may vary over the course of opioid-use disorder.”

Conclusions

Further research could clarify if findings from this study hold in other settings. If they do, the authors see a need for finding interventions to reduce criminal activity among buprenorphine patients, and perhaps for using criminal activity as a variable when matching patients to the best treatment.

Reference

Rastegar DA, Kawasaki SS, King VL, Harris EE, Brooner RK. Criminal charges prior to and after enrollment in opioid agonist treatment: A comparison of methadone maintenance and office-based buprenorphine [Epub ahead of print April 20, 2016]. doi: 10.3109/10826084.2016.1155608. PMID: 27097276.  http://dx.doi.org/10.3109/10826084.2016.1155608

Filed Under: 2016, 27-3, Newsletter

Primary Sidebar

Upcoming Events

CADCA 2023 Leadership Forum and SAMHSA’s Prevention Day
January 30-February 3, 2023

Washington, D.C.
http://cadca.org/forum2023

2023 Rx and Illicit Drug Summit
April 10-13, 2023

Atlanta, Georgia
https://www.rx-summit.com/

2023 ASAM conference
April 13-16, 2023

Washington, D.C.
https://annualconference.asam.org/

 

View More Upcoming Events…

ATForum.com

  • Newsletter
  • Addiction Resources
  • Rx Methadone & Safety
  • Patient Education Brochures
  • Events
  • Related Websites

Addiction Resources

  • Addiction and Recovery
  • Addiction Treatment Forum
  • Books and Booklets of Interest
  • Drug Screening and Testing
  • Evidence-Based Addiction Medicine
  • Federal Government
  • Health Care Reform
  • Hepatitis, HIV/AIDS
  • Medication-Assisted Treatment
  • Mental Health
  • Miscellaneous
  • Online Continuing Education Free Training Modules

Footer

Addiction Treatment Forum is produced by an independent medical communications agency. Commercial advertising is not accepted.
Published by Clinco Communications, Inc.
About Us
Contact Us
Privacy Policy
Terms of Use
Follow Us

Sign up for News!

© 2023 Addiction Treatment Forum · All Rights Reserved